John Ma joins Smith+Nephew's Board as NED

RNS Number : 5235O

Smith & Nephew Plc

10 February 2021

 

John Ma joins Smith+Nephew's Board as
Non-Executive Director

10 February 2021

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce the appointment of Dr John Ma as a Non-Executive Director.

Dr Ma is an established leader within the MedTech industry with a deep knowledge of the Asia-Pacific region and of surgical robotics, both significant areas of opportunity for Smith+Nephew.

Since 2019 Dr Ma has served as Chief Executive Officer and Chair of Ronovo Surgical, a start-up soft tissue surgical robotics business he founded. His previous executive experience includes Senior Vice President, Strategic Growth Initiatives at Intuitive Surgical, President of Fosun Health Holding and VP and General Manager, Central China for GE Healthcare. Previous non-executive director experience includes Hong Kong-listed Haier Electronics and Hong Kong and Shanghai-listed Fosun Pharma.

Dr Ma holds a Ph.D. in Materials Science and Engineering from Wayne State University, USA.

Roberto Quarta, Chair of Smith+Nephew, said:

"We are delighted to have secured a Board colleague with John's track record growing medical device businesses across China and the wider region. I am confident that his expertise will further help us support the management team's strategic ambitions."

John Ma will join the Board on 17 February 2021.

-ENDS-

Enquiries

Investors
Andrew Swift	[phone]
Smith+Nephew
Media
Charles Reynolds	[phone]
Smith+Nephew
Susan Gilchrist / Ayesha Bharmal	[phone]
Brunswick

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit  www.smith-nephew.com  and follow us on  Twitter ,  LinkedIn ,  Instagram  or  Facebook .

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

^◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

 

END

 

 

BOAEAKANELKFEFA